Business Wire · October 26, 2026

Aulos Bioscience's Imneskibart With Avelumab Delivers Exceptional Progression-Free Survival in Checkpoint Inhibitor-Refractory Adenocarcinoma Non-Small Cell Lung Cancer

Get the app for more

Explore stock news, insights and company research.